The role of brachytherapy in the treatment of glioblastoma multiforme (Q38834847)

6 September 2017

1 reference

title

The role of brachytherapy in the treatment of glioblastoma multiforme (English)

1 reference

6 September 2017

1 reference

1 reference

7

Ricardo J Komotar

1 reference

6 September 2017

Eric Barbarite

1

1 reference

6 September 2017

Justin T Sick

2

1 reference

6 September 2017

Emmanuel Berchmans

3

1 reference

6 September 2017

Amade Bregy

4

1 reference

6 September 2017

Ashish H Shah

5

1 reference

6 September 2017

Nagy Elsayyad

6

1 reference

6 September 2017

16 May 2016

1 reference

6 September 2017

1 reference

6 September 2017

40

1 reference

6 September 2017

195-211

1 reference

6 September 2017

2

1 reference

Systemic iodine 125 activity after GliaSite brachytherapy: safety considerations.

6 September 2017

1 reference

https://api.crossref.org/works/10.1007%2FS10143-016-0727-6

Survival analysis of HDR brachytherapy versus reoperation versus temozolomide alone: a retrospective cohort analysis of recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10143-016-0727-6

Combined salvage therapies for recurrent glioblastoma multiforme: evaluation of an interdisciplinary treatment algorithm.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10143-016-0727-6

Treatment of recurrent glioblastoma multiforme with GliaSite brachytherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10143-016-0727-6

High-dose-rate stereotactic brachytherapy for patients with newly diagnosed glioblastoma multiformes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10143-016-0727-6

Phase I trial of gross total resection, permanent iodine-125 brachytherapy, and hyperfractionated radiotherapy for newly diagnosed glioblastoma multiforme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10143-016-0727-6

Feasibility and safety of outpatient brachytherapy in 37 patients with brain tumors using the GliaSite Radiation Therapy System

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10143-016-0727-6

Neurologic complications of radiation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10143-016-0727-6

Safety and efficacy of permanent iodine-125 seed implants and carmustine wafers in patients with recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10143-016-0727-6

Increasing incidence of glioblastoma multiforme and meningioma, and decreasing incidence of Schwannoma (2000-2008): Findings of a multicenter Australian study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10143-016-0727-6

Perioperative high-dose-rate brachytherapy in the treatment of recurrent malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10143-016-0727-6

Radiation necrosis: relevance with respect to treatment of primary and secondary brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10143-016-0727-6

GliaSite brachytherapy for treatment of recurrent malignant gliomas: a retrospective multi-institutional analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10143-016-0727-6

Operation and permanent low activity 125I brachytheraphy for recurrent high-grade astrocytomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10143-016-0727-6

Assumptions in the radiotherapy of glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10143-016-0727-6

Differentiation of cerebral radiation necrosis from tumor recurrence by proton magnetic resonance spectroscopy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10143-016-0727-6

Low-dose rate stereotactic iodine-125 brachytherapy for the treatment of inoperable primary and recurrent glioblastoma: single-center experience with 201 cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10143-016-0727-6

CT guided interstitial high dose rate brachytherapy for recurrent malignant gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10143-016-0727-6

Randomized study of brachytherapy in the initial management of patients with malignant astrocytoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10143-016-0727-6

Evaluation of dynamic contrast-enhanced T1-weighted perfusion MRI in the differentiation of tumor recurrence from radiation necrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10143-016-0727-6

Permanent iodine 125 brachytherapy in patients with progressive or recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10143-016-0727-6

Results of stereotactic brachytherapy used in the initial management of patients with glioblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10143-016-0727-6

Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10143-016-0727-6

The diagnosis and treatment of pseudoprogression, radiation necrosis and brain tumor recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10143-016-0727-6

Permanent iodine-125 interstitial implants for the treatment of recurrent glioblastoma multiforme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10143-016-0727-6

Laser interstitial thermal therapy for focal cerebral radiation necrosis: a case report and literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10143-016-0727-6

The Brain Tumor Cooperative Group NIH Trial 87-01: a randomized comparison of surgery, external radiotherapy, and carmustine versus surgery, interstitial radiotherapy boost, external radiation therapy, and carmustine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10143-016-0727-6

Radiation necrosis in the brain: imaging features and differentiation from tumor recurrence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10143-016-0727-6

Conservative treatment of delayed cerebral radiation necrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10143-016-0727-6

Effects of iodine-125 brachytherapy on the proliferative capacity and histopathological features of glioblastoma recurring after initial therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10143-016-0727-6

Brachytherapy of glioblastoma recurring in previously irradiated territory: predictive value of tumor volume.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10143-016-0727-6

Comparison of (11)C-methionine, (11)C-choline, and (18)F-fluorodeoxyglucose-PET for distinguishing glioma recurrence from radiation necrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10143-016-0727-6

Interstitial irradiation for CNS lesions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10143-016-0727-6

CT-guided interstitial HDR brachytherapy for recurrent glioblastoma multiforme. Long-term results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10143-016-0727-6

Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10143-016-0727-6

Use of the RTOG recursive partitioning analysis to validate the benefit of iodine-125 implants in the primary treatment of malignant gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10143-016-0727-6

Reversal of cerebral radiation necrosis with bevacizumab treatment in 17 Chinese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10143-016-0727-6

Immediate post-operative brachytherapy prior to irradiation and temozolomide for newly diagnosed glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10143-016-0727-6

GliaSite brachytherapy boost as part of initial treatment of glioblastoma multiforme: a retrospective multi-institutional pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10143-016-0727-6

Long term results of stereotactic brachytherapy used in the initial treatment of patients with glioblastomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10143-016-0727-6

Bevacizumab reverses cerebral radiation necrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10143-016-0727-6

Role of magnetic resonance spectroscopy for the differentiation of recurrent glioma from radiation necrosis: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10143-016-0727-6

Results of interstitial brachytherapy for malignant brain tumors.

21 January 2018

1 reference

12 December 2020

Survival prognostic factors in patients with glioblastoma: our experience.

1 reference

12 December 2020

Image fusion-guided stereotactic iodine-125 interstitial irradiation of inoperable and recurrent gliomas.

1 reference

12 December 2020

Treatment results of stereotactic interstitial brachytherapy for primary and metastatic brain tumors

1 reference

12 December 2020

Patterns of recurrence of glioblastoma multiforme after external irradiation followed by implant boost.

1 reference

12 December 2020

Comparison of stereotactic radiosurgery and brachytherapy in the treatment of recurrent glioblastoma multiforme

1 reference

12 December 2020

Therapeutic irradiation and brain injury

1 reference

12 December 2020

Cerebral radiation necrosis

1 reference

12 December 2020

External irradiation followed by an interstitial high activity iodine-125 implant “boost” in the initial treatment of malignant gliomas: NCOG study 6G-82-2 gliomas: NCOG study 6H-82-2

1 reference

12 December 2020

Interstitial brachytherapy for newly diagnosed patients with malignant gliomas: the UCSF experience

1 reference

12 December 2020

High activity iodine-125 interstitial implant for gliomas

1 reference

12 December 2020

Brachytherapy: Results of two different therapy strategies for patients with primary glioblastoma multiforme.

1 reference

12 December 2020

10.1007/S10143-016-0727-6

Identifiers

DOI

1 reference

6 September 2017

1 reference